We report two cases of tuberculosis (TB) after treatment with infliximab (IFX) for rheumatoid arthritis (RA). The first case, a 69-year-old woman with RA, developed miliary TB with acute respiratory distress syndrome 21 months after initiation of IFX therapy. Sputum samples revealed smears and cultures positive for Mycobacterium tuberculosis and also positive polymerase chain reaction for TB (PCR-TB); in addition urine samples were smear-negative and culture-positive for TB. She was treated with corticosteroid pulse therapy and anti-tuberculosis drugs, and recovered. The second case, a 51-year-old man with RA, had had contact with a tuberculosis patient four years after initiation of IFX therapy. One year later, he developed pulmonary and pleural tuberculosis. Mycobacterium tuberculosis was detected in the bronchial lavage fluid and pleural effusion (smear-negative and culture- and PCR-TB positive). He clinically improved by treatment with anti-tuberculosis drugs. In both cases, the enzyme-linked immunosorbent spot (ELISPOT) tests revealed positive responses although the QuantiFERON TB-2G tests were not positive. We suggest that the ELISPOT test may be useful as a supportive diagnostic tool for tuberculosis in immunocompromised conditions including RA treated with a tumor necrosis factor-alpha (TNF-alpha) inhibitor.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cases tuberculosis
8
tuberculosis treatment
8
rheumatoid arthritis
8
initiation ifx
8
ifx therapy
8
mycobacterium tuberculosis
8
anti-tuberculosis drugs
8
tuberculosis
7
positive
5
[two cases
4

Similar Publications

The dire struggle: India's unfulfilled promise to eliminate tuberculosis.

Indian J Med Ethics

January 2025

Consultant Gastroenterologist, Kalinga Gastroenterology Foundation, Bajrakabati Road, Cuttack, Odisha, 753007, INDIA.

In 2023, as per the World Health Organization (WHO), India emerged as the country with the highest number of tuberculosis (TB) cases, reporting 2.8 million cases and contributing to 27% of the global TB burden [1]. Worldwide, there were 7.

View Article and Find Full Text PDF

Risk Factors for Disseminated Tuberculosis and Associated Survival in Adults Without Human Immunodeficiency Virus.

Open Forum Infect Dis

January 2025

Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

Background: The global resurgence of disseminated tuberculosis (TB) after the coronavirus disease 2019 pandemic highlights the necessity of understanding host risk factors, especially in adults without human immunodeficiency virus.

Methods: We reviewed TB cases admitted to Shanghai Public Health Clinical Center from 2017 to 2022. We analyzed baseline characteristics and outcomes.

View Article and Find Full Text PDF

Background: Tuberculosis (TB) is a leading cause of death worldwide with over 90% of reported cases occurring in low- and middle-income countries (LMICs). Pre-treatment loss to follow-up (PTLFU) is a key contributor to TB mortality and infection transmission.

Objectives: We performed a scoping review to map available evidence on interventions to reduce PTLFU in adults with pulmonary TB, identify gaps in existing knowledge, and develop a conceptual framework to guide intervention implementation.

View Article and Find Full Text PDF

Background: Among occupational hazards in healthcare settings, latent tuberculosis infection (LTBI) ranks as a major concern, particularly threatening healthcare workers (HCWs) in nations grappling with intermediate to high tuberculosis (TB) rates. Our study was conducted in Morocco, a country characterized by widespread Bacillus Calmette-Guérin (BCG) vaccination and a moderate TB burden of 93 cases per 100,000 inhabitants in 2022. We examined both the prevalence of LTBI among Moroccan HCWs and its various risk factors.

View Article and Find Full Text PDF

Successfully treating tuberculosis (TB) could significantly help reduce its spread. The aim of this study was to identify factors associated with successful TB treatment. A retrospective study was conducted in West Nusa Tenggara, Indonesia, using data from the National TB Information System (SITB) covering patients from January 1 to December 31, 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!